Adaptive Smoking Cessation Using Precessation Varenicline or Nicotine Patch: A Randomized Clinical Trial.
Adaptive Smoking Cessation Using Precessation Varenicline or Nicotine Patch: A Randomized Clinical Trial.
复制标题
DOI：
10.1001/jamanetworkopen.2023.32214
复制
发表时间：
2023-09-05
影响因子：
13.8
通讯作者：
Rose, Jed E.
中科院分区：
文献类型：
--
作者：
Davis, James M.;Masclans, Luisa;Rose, Jed E.
Is adaptive pharmacotherapy effective for smoking cessation compared with nonadaptive standard pharmacotherapy? In this randomized clinical trial, 188 smokers chose between varenicline and nicotine patches and were then randomized to adaptive or standard treatment. Biochemically verified 30-day continuous smoking abstinence at 12 weeks after the target quit date was significantly higher for the adaptive treatment group than the standard treatment group. These findings suggest that adaptive pharmacotherapy was effective for smoking cessation. This randomized clinical trial assesses the efficacy of adaptive pharmacotherapy compared with standard pharmacotherapy using varenicline or nicotine patches for smoking cessation. Adaptive pharmacotherapy, ie, starting a medication regimen and then modifying that regimen based on patient response, is common in many medical domains but is not common in smoking cessation. Recently, studies have found that adaptive treatment using precessation nicotine patches is efficacious for smoking cessation; however, adaptive treatment using precessation varenicline and adaptive treatment in clinical practice settings have not been fully assessed. To determine whether adaptive pharmacotherapy leads to higher smoking abstinence rates than standard pharmacotherapy in a clinical practice setting. This double-blinded stratified placebo-controlled randomized clinical trial compared adaptive treatment with standard treatment for smoking cessation. The study was conducted at a university health system in Durham, North Carolina, from February 2018 to May 2020 and was stopped early due to COVID-19. Data were analyzed as intent-to-treat from May 24, 2021, to February 27, 2022. Participants were allowed to choose varenicline or nicotine patches and were then randomized to adaptive or nonadaptive (standard) treatment. Participants started on their chosen medication (adaptive) or placebo (standard) 4 weeks before their target quit day. Two weeks later, participants were assessed for treatment response. Adaptive participants who did not decrease daily cigarettes smoked by at least 50% (nonresponders) received bupropion in addition to their chosen medication. Participants in the adaptative treatment group who did decrease daily cigarettes smoked by at least 50% (responders) and participants in the standard treatment group received additional placebo bupropion. Participants in the standard treatment group received varenicline starting 1 week before the target quit date or nicotine patches starting on the target quit day. All participants received brief behavioral support. The main outcome was biochemically verified 30-day continuous smoking abstinence 12 weeks after their target quit smoking day. Other measures included demographic characteristics, smoking history, and repeated smoking assessments. Of the planned 300 participants, a total of 188 participants (mean [SD] age, 49.1 [12.5] years; 102 [54%] female) were enrolled before the trial was stopped because of the COVID-19 pandemic. A total of 127 participants chose to use varenicline, including 64 randomized to adaptive treatment and 63 randomized to standard treatment, and 61 participants chose to use nicotine patches, including 31 randomized to adaptive treatment and 30 randomized to standard treatment. At baseline, participants smoked a mean (SD) of 15.4 (7.3) cigarettes per day. At 12 weeks after the target quit day, biochemically verified 30-day continuous smoking abstinence was observed in 23 of 95 participants (24%) in the adaptive treatment group and 8 of 93 participants (9%) in the standard treatment (odds ratio [OR], 3.38; 95% CI, 1.43-7.99; P = .004); among participants who used varenicline, 30-day continuous abstinence was 18 participants (28%) in the adaptive treatment group, and 5 participants (8%) in the standard treatment group (OR, 4.54; 95% CI, 1.57-13.15); among participants who used nicotine patches, 30-day continuous abstinence was 5 participants (16%) in the adaptive treatment group and 3 participants (10%) in the standard treatment group (OR, 1.73; 95% CI, 0.38-7.99). Sleep problems were more common for participants in the varenicline adaptive treatment group than in the varenicline standard treatment group (rate ratio, 1.74; 95% CI, 1.18-2.58; P = .03). This randomized clinical trial found that adaptive pharmacotherapy was efficacious for smoking cessation treatment in a practice setting. ClinicalTrials.gov Identifier: NCT02501265
登录
查看更多内容
影响因子：
--
作者：
Hajek, Peter;McRobbie, Hayden J.;Dhanji, Al-Rehan
通讯作者：
Dhanji, Al-Rehan
影响因子：
5.7
作者：
Rose, Jed E.;Behm, Frederique M.;Uhl, George R.
通讯作者：
Uhl, George R.
影响因子：
1.4
作者：
Cahill, Kate;Stead, Lindsay F.;Polonio, Igor Bastos
通讯作者：
Polonio, Igor Bastos
影响因子：
4.7
作者：
Hawk, Larry W., Jr.;Ashare, Rebecca L.;Mahoney, Martin C.
通讯作者：
Mahoney, Martin C.
影响因子：
4.7
作者：
Rose, Jed E.;Herskovic, Joseph E.;Westman, Eric C.
通讯作者：
Westman, Eric C.